UPDATED: Synthego exits stealth with CRISPR/Cas9 genome editing technologies

Synthego has emerged from stealth mode equipped with guide RNA products for use in CRISPR/Cas9 genome engineering. The company, which was founded by ex-SpaceX computer engineers, is using automation to deliver synthetic guide RNA products at a cost, speed and quality it claims sets it apart from the competition.

Redwood City, CA-based Synthego is building its business upon CRISPRevolution, a portfolio of guide RNA products for use in genome editing. Other, larger organizations, such as GE Life Sciences ($GE), already offer CRISPR guide RNA, but Synthego is claiming it can undercut the competition in terms of speed and cost while achieving cutting efficiency of up to 90%. Synthego’s basic CRISPR RNA kit costs $79 for enough material for 10 to 20 transfections and ships in three to 5 days.

To achieve these costs and timelines, ex-SpaceX computer engineers Michael and Paul Dabrowski, who list stints at now-defunct sequencing startup Halcyon Molecular on their résumés, have worked with recruits from firms including Bio-Rad Laboratories ($BIO) to build software-enabled, automated production workflows.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

“Synthego is the merger of biology and engineering to create a well-oiled genome engineering solutions company,” Synthego CEO and Cofounder Paul Dabrowski said in a statement. “Our platform minimizes the variables and risks in biological research by automating workflows, controlling quality, scaling for massive experiments and reducing cost structures.”

Dabrowski and his collaborators have persuaded Founders Fund, Menlo Ventures and WI Harper Group to invest in their plans. Founders Fund, Peter Thiel’s investment shop, also invested in Halcyon Molecular, which went from talking up $100, 10-minute genome sequencing in 2009 to shutting its doors for the last time in 2012.

Synthego revealed $8.3 million in financing from unidentified investors in a SEC filing in 2013 and has quietly topped up its coffers since then. "The company has closed a number of smaller, private rounds with the latest in early 2016," Dabrowski told FierceBiotechIT. Now, with Synthego exiting stealth, Dabrowski is talking to investors once again. "The company will be raising a larger equity round in the fall of 2016," he said.

- read the release

Related Articles:
Editas partners to bring CRISPR to gene therapy in inherited retinal diseases
CRISPR simulation upstart taps Celgene, Data Collective for cash


Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.